In its update, GSK reported a 17% rise in specialty medicines across its HIV, cancer, and respiratory business to £2.93 ...

Now, after nearly three decades, the U.S. Food and Drug Administration (FDA) has approved Blujepa (gepotidacin), a new oral antibiotic from GSK, offering fresh hope for those struggling with ...

EAGLE-1 trial data shows gepotidacin’s potential in treating gonorrhoea, for which no new antibiotics have been approved ...

UTIs are the cause of roughly 8 million emergency room visits and 100,000 hospitalizations in the US each year, GSK said.

GSK’s gepotidacin is a first-in-class ... In March 2025, the drug received FDA approval under the brand name Blujepa for the treatment of females aged 12 years and older and weighing 40kg ...

Blujepa (gepotidacin) is a new antibiotic recently approved by the FDA for treating bladder infections caused by certain bacteria in women and girls ages 12 and older. Blujepa works differently ...

It could be the first new treatment for gonorrhea in 30 years. It could be the first new treatment for the infection in 30 ...

The appendix is thought to play a role in all of this by producing inflammatory proteins that trigger the body to produce cascades of immune responses, according to a report of the study published in ...

Gepotidacin inhibits DNA replication via two ... could claim 10 million deaths a year by 2050. "The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in ...

The pill, called gepotidacin, was approved by the Food and Drug Administration in March to treat uncomplicated urinary tract infections in women and girls 12 and up — the most common type of infection ...